Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy

Abstract

Background We have previously reported the superior feasibility and safety of adjuvant S-1 plus docetaxel in patients with stage III gastric cancer during a prospective phase II study. We report 3-year follow-up data on patients enrolled in this study. Patients and methods Fifty-three patients with histologically confirmed stage III gastric cancer who underwent gastrectomy with D2 lymphadenectomy were enrolled into this study. They received oral S-1 (80 mg/m 2 /day) for 2 consecutive weeks and intravenous docetaxel (40 mg/m 2 ) on day 1, repeated every 3 weeks (one cycle). Treatment was initiated within 45 days after surgery and repeated for four cycles, followed by S-1 monotherapy (4 weeks on, 2 weeks off) until 1 year after surgery. Three-year overall survival (OS) and disease-free survival (DFS) were evaluated. Results The OS rate at 3 years was 78.4 % [95 % confidence interval (CI), 67.9-90.6 %] and the DFS rate at 3 years was 66.2 % (95 % CI, 54.4-80.7 %). Subgroup analyses according to disease stage showed a 3-year OS and DFS rate of 85.7 % (95 % CI, 74.9-98.1 %) and 70.8 % (95 % CI, 57.1-87.8 %) for stage IIIA, and 62. 123Gastric Cancer (2014( ) 17:348-353 DOI 10.1007 yielded promising OS and DFS in stage IIIA gastric cancer patients who had undergone D2 gastrectomy. We believe that this regimen is a candidate for future phase III trials studying the optimal adjuvant chemotherapy regimen for stage III gastric cancer.

Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations

“…Next to brain, bone is a frequent site of metastasis in NSCLC exerting a negative impact on quality of life 31,32. Bone metastasis was an independent negative predictive factor for OS in patients with mutated and wild-type EGFR 33. In this study, we achieved a median PFS and OS of 4.8 and 12.9 months for NSCLC patients with bone metastasis, respectively.…”

The predictive value of the preoperative C-reactive protein–albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data

“…A total of 256 patients (63.8%) received adjuvant chemotherapy, with the median number of cycles being 5 (range 1-12), similar to a previous study [23]. According to the cycles they completed, the patients were divided into the following three groups: group A: patients who did not receive any chemotherapy treatment; group B: patients who completed 1-3 cycles of chemotherapy; and group C: patients who completed more than three cycles of chemotherapy [24].…”

Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIA gastric cancer after D2 gastrectomy

“…The National Comprehensive Cancer Network (NCCN) has suggested that postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors [7]. Data from population-based studies and analysis of clinical trials demonstrate that the survival of patients with gastric cancer has improved with the use of newer chemotherapeutic agents [8]. In particular, inadequate evidence is available on optimal duration of chemotherapy and the number of administered cycles is generally based on patient responsiveness and individual tolerability as well as physician preferences.…”